Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infection
Kasha P Singh, Jennifer M Zerbato, Wei Zhao, Sabine Braat, Claire Deleage, G Surekha Tennakoon, Hugh Mason, Ashanti Dantanarayana, Ajantha Rhodes, Jake W Rhodes, Joe Torresi, Andrew N Harman, Peter A Revill, Megan Crane, Jacob D Estes, Anchalee Avihingsanon, Sharon R Lewin, Jennifer Audsley
PLOS PATHOGENS | PUBLIC LIBRARY SCIENCE | Published : 2020
In HIV-hepatitis B virus (HBV) co-infection, adverse liver outcomes including liver fibrosis occur at higher frequency than in HBV-mono-infection, even following antiretroviral therapy (ART) that suppresses both HIV and HBV replication. To determine whether liver disease was associated with intrahepatic or circulating markers of inflammation or burden of HIV or HBV, liver biopsies and blood were collected from HIV-HBV co-infected individuals (n = 39) living in Bangkok, Thailand and naïve to ART. Transient elastography (TE) was performed. Intrahepatic and circulating markers of inflammation and microbial translocation were quantified by ELISA and bead arrays and HIV and HBV infection quantifi..View full abstract
Related Projects (3)
Awarded by National Cancer Institute, National Institutes of Health
This work was supported by the National Health and Medical Research Council (NHMRC) of Australia https://www.nhmrc.gov.au; including an NHMRC project grant (SRL, KS, MC, JA), NHMRC program grant (SRL), practitioner fellowship (SRL) and an NHMRC biomedical postgraduate scholarship (KS). This project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health https://www.cancer.gov; under Contract No. 75N91019D00024 (formerly HHSN261200800001E). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.https://www.nhmrc.gov.au The Funding organisations had no role in study design, data collection and analysis, decision to publish or manuscript preparation.